Crowdsourcing Patent Examination with the Patent Prosecution Highway
What You Need to Know
Key takeaway #1
The PPH can be a useful tool for streamlining global prosecution of corresponding patent applications—which in turn can reduce costs and increase the chances of successful prosecution.
Client Alert | 12 min read | 05.15.23
|
The Patent Prosecution Highway (PPH) is a work-share arrangement between the patent offices of different countries. It allows for participating patent offices to share—and thus benefit from—work already performed by other participating patent offices. In short, when a claim (or claims) of a patent application is allowed in a first patent office, a PPH request may be made to fast-track the examination of a corresponding application in a second patent office based on that allowance. So, for example, when a U.S. patent application is allowed, that allowance can be used to fast-track examination in corresponding foreign applications—or vice versa. For U.S. applicants, the USPTO also requires that: (1) the claims of the U.S. application correspond in scope to the allowed claims of the foreign application, and (2) substantive examination of the U.S. application has not yet begun. Other countries’ requirements may differ. Successfully utilizing the PPH can significantly reduce the time it takes for the second patent office to conduct its examination—and it is intended to do just that. While additional benefits may vary from country to country, applications examined under the PPH also generally have higher rates of allowance and suffer less from duplicative examination. |  |
These benefits can streamline global prosecution and reduce overall costs for applicants, particularly in view of the ever growing number of countries participating in PPH programs. Presently, the USPTO has PPH agreements with patent offices of the Europe Union, United Kingdom, China, Japan, Taiwan, Mexico, Israel and several other countries and regions.
For additional information on the PPH, including country specific requirements and PPH strategies for your patent portfolio, please contact your trusted partners at Crowell & Moring.
Insights
Client Alert | 9 min read | 07.09.25
In our first alert in our new weekly series on the EU Pharma Package, we provided some important background and general information about the status of the Pharma Package and how the trilogues work. In this second alert, we will discuss the respective positions of the European Commission, the European Parliament and the Council of the European Union with respect to one of the most debated and anxiously anticipated topics on the table, the regulatory data protection (RDP).
Client Alert | 3 min read | 07.08.25
Client Alert | 3 min read | 07.08.25
DOJ and HHS Launch FCA Working Group: Heightened Enforcement Risk for Health Care Entities
Client Alert | 5 min read | 07.08.25
